Guardant 360® Liquid Biopsy Advances Clinical Trial Enrollment
Dr. Justin Odegaard, VP of Clinical Development at Guardant Health discusses a new study published in “Nature Medicine” (Oct 2020) which finds that the Guardant360® liquid biopsy rapid blood test is not only concordant to tissue biopsy, but more than doubles clinical trial enrollment and achieves similar treatment response and survival rates in patients with advanced gastrointestinal cancer.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Key Takeaways
- Key Point: Justin Odegaard, VP of Clinical Development at Guardant Health discusses a new study published in “Nature Medicine” (Oct 2020) which finds that the Guardant360® liquid biopsy r…
- Key Point: Justin Odegaard is currently Vice President of Clinical Development at Guardant Health, where he leads Guardant’s clinical trials and companion diagnostic development.
- Key Point: Odegaard was Director of molecular pathology at Lifecode and adjunct attending faculty at Stanford University Hospital.
- Key Point: He received his PhD in immunology and his MD from Stanford University, where he later trained in and practiced both surgical pathology and molecular pathology.
- Key Point: Health Professional Radio · Guardant 360® Liquid Biopsy Advances Clinical Trial Enrollment
Dr. Justin Odegaard is currently Vice President of Clinical Development at Guardant Health, where he leads Guardant’s clinical trials and companion diagnostic development. Prior to Guardant, Dr. Odegaard was Director of molecular pathology at Lifecode and adjunct attending faculty at Stanford University Hospital. He received his PhD in immunology and his MD from Stanford University, where he later trained in and practiced both surgical pathology and molecular pathology.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.



